Private Trust Co. NA Has $95,000 Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Private Trust Co. NA raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 19.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,166 shares of the medical equipment provider’s stock after buying an additional 191 shares during the period. Private Trust Co. NA’s holdings in Hologic were worth $95,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of HOLX. Janus Henderson Group PLC grew its stake in Hologic by 29.5% in the first quarter. Janus Henderson Group PLC now owns 99,707 shares of the medical equipment provider’s stock valued at $7,773,000 after purchasing an additional 22,732 shares in the last quarter. B. Riley Wealth Advisors Inc. grew its stake in shares of Hologic by 13.0% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 3,198 shares of the medical equipment provider’s stock valued at $249,000 after buying an additional 367 shares in the last quarter. Tidal Investments LLC increased its holdings in Hologic by 10.8% in the first quarter. Tidal Investments LLC now owns 16,901 shares of the medical equipment provider’s stock worth $1,317,000 after buying an additional 1,654 shares during the last quarter. Comerica Bank raised its position in Hologic by 40.9% during the first quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock valued at $8,580,000 after acquiring an additional 31,967 shares in the last quarter. Finally, iA Global Asset Management Inc. acquired a new stake in Hologic in the first quarter valued at approximately $37,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Up 0.1 %

HOLX opened at $79.50 on Friday. The business has a 50 day moving average of $80.22 and a 200-day moving average of $78.42. The stock has a market capitalization of $18.47 billion, a price-to-earnings ratio of 23.84, a P/E/G ratio of 2.50 and a beta of 0.98. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same period in the prior year, the firm earned $0.89 EPS. The business’s revenue was up 4.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HOLX. UBS Group raised their price target on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Mizuho reduced their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Royal Bank of Canada upped their price target on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. raised their price objective on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Finally, Raymond James upped their target price on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Hologic has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.